Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
600
Recruiting, industry sponsors, Oncology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting600
- Completed2,063
600 trials
Showing 1 to 25, recently updated first.
AstraZenecaAstraZeneca (AZN)
NCT06103864 · 625 participants (planned) · Start Nov 23, 2023 · Primary completion Jul 28, 2027
Drug: Dato-DXd; Durvalumab and 5 more · For: Breast Cancer
Sites: Daphne, Alabama; Springdale, Arkansas; Duarte, California · 318 sites in all
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07578649 · 600 participants (planned) · Start Nov 5, 2026 · Primary completion Sep 29, 2029
Drug: PF-08634404; Pembrolizumab and 1 more · For: Endometrial Neoplasms; Endometrial Cancer
Sites: Jupiter, Florida; Orlando, Florida; Coon Rapids, Minnesota · 54 sites in all
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPivotal-lookingRecruiting
Pierre Fabre MedicamentIndustry
NCT03394365 · 115 participants (planned) · Start Dec 29, 2017 · Primary completion May 31, 2030
Drug: tabelecleucel · For: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders and 2 more
Sites: Duarte, California; La Jolla, California; Loma Linda, California · 72 sites in all
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07062965 · 400 participants (planned) · Start Aug 5, 2025 · Primary completion Jul 22, 2027
Drug: PF-07248144; Fulvestrant and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Gilbert, Arizona · 432 sites in all
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT07085767 · 1,000 participants (planned) · Start Nov 3, 2025 · Primary completion Dec 2028
Drug: Palazestrant; Letrozole-matching placebo and 3 more · For: Breast Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer and 2 more
Sites: Hot Springs, Arkansas; Beverly Hills, California; La Jolla, California · 209 sites in all
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07392892 · 840 participants (planned) · Start May 14, 2026 · Primary completion Jul 22, 2031
Drug: PF-08634404; Chemotherapy and 1 more · For: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma; Metastatic Gastric Cancer; Gastroesophageal Junction Cancer and 1 more
Sites: Anaheim, California; Atascadero, California; Burbank, California · 124 sites in all
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07222566 · 1,410 participants (planned) · Start Jan 6, 2026 · Primary completion Feb 27, 2029
Drug: PF-08634404; Pembrolizumab and 2 more · For: Advanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung and 3 more
Sites: Bullhead City, Arizona; Chandler, Arizona; Gilbert, Arizona · 560 sites in all
- Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07222800 · 800 participants (planned) · Start Dec 11, 2025 · Primary completion Feb 23, 2030
Drug: PF-08634404; Bevacizumab and 1 more · For: Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms and 7 more
Sites: Chandler, Arizona; Gilbert, Arizona; Glendale, Arizona · 401 sites in all
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566052 · 356 participants (planned) · Start Aug 19, 2026 · Primary completion Jun 30, 2030
Drug: Setidegrasib; Docetaxel · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Glendale, California; Los Angeles, California; San Francisco, California · 38 sites in all
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)Pivotal-lookingRecruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06615479 · 440 participants (planned) · Start Mar 12, 2025 · Primary completion Dec 30, 2027
Drug: BMS-986393; Cyclophosphamide and 5 more · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 141 sites in all
- Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
Norroy Bioscience Co., LTDIndustry
NCT07795268 · 600 participants (planned) · Start Nov 13, 2026 · Primary completion Nov 30, 2028
Drug: 177Lu-NYM032 injection · For: Prostate Cancer
Sites: Beijing, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06926868 · 600 participants (planned) · Start Sep 11, 2025 · Primary completion Mar 13, 2028
Drug: Iza-bren; Nab-paclitaxel and 4 more · For: Breast Neoplasms
Sites: Hot Springs, Arkansas; Cerritos, California; Long Beach, California · 296 sites in all
AbbVieAbbVie (ABBV)
NCT07525206 · 990 participants (planned) · Start May 22, 2026 · Primary completion May 2029
Drug: Telisotuzumab adizutecan; Bevacizumab and 1 more · For: Colorectal Cancer
Sites: Goodyear, Arizona; Springdale, Arkansas; Duarte, California · 91 sites in all
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPivotal-lookingRecruiting
Bicara TherapeuticsIndustry
NCT06788990 · 650 participants (planned) · Start Jan 28, 2025 · Primary completion Apr 2028
Drug: Ficerafusp alfa; Pembrolizumab (KEYTRUDA®) and 1 more · For: Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 242 sites in all
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)Pivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566156 · 390 participants (planned) · Start May 11, 2026 · Primary completion Mar 31, 2030
Drug: Enfortumab vedotin; Cisplatin and 4 more · For: Urothelial Cancer; Urinary Bladder Neoplasms
Sites: Little Rock, Arkansas; Santa Barbara, California; Aurora, Colorado · 37 sites in all
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT06282575 · 286 participants (planned) · Start Jul 19, 2024 · Primary completion Dec 1, 2028
Drug: Zanidatamab; Cisplatin and 3 more · For: Biliary Tract Cancer
Sites: Duarte, California; Lone Tree, Colorado; Orlando, Florida · 185 sites in all
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Pivotal-lookingRecruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT04613596 · 626 participants (planned) · Start Dec 2, 2020 · Primary completion Oct 31, 2028
Drug: Adagrasib; Adagrasib and 3 more · For: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Sites: Goodyear, Arizona; Prescott Valley, Arizona; Safford, Arizona · 776 sites in all
- (Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal TumorsPivotal-lookingRecruiting
Cogent Biosciences, Inc.Industry
NCT05208047 · 482 participants (planned) · Start Apr 14, 2022 · Primary completion Sep 30, 2025
Drug: Bezuclastinib; Bezuclastinib and 7 more · For: Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 126 sites in all
AbbVieAbbVie (ABBV)
NCT07581002 · 660 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2032
Drug: Pivekimab Sunirine; Venetoclax and 2 more · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Atlanta, Georgia · 40 sites in all
- Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerPivotal-lookingRecruiting
Shanghai Yizhong Pharmaceutical Co., Ltd.Industry
NCT06143553 · 168 participants (planned) · Start Sep 25, 2023 · Primary completion Dec 31, 2027
Drug: Paclitaxel Polymeric Micelles for Injection; Eribulin Mesilate injection and 4 more · For: Metastatic Breast Cancer (MBC)
Sites: Nanjing, China; Shanghai, China · 3 sites in all
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07555938 · 380 participants (planned) · Start Jun 23, 2026 · Primary completion Nov 30, 2028
Drug: Cevostamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; New Haven, Connecticut · 105 sites in all
- Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaPivotal-lookingRecruiting
Quetzal TherapeuticsIndustry
NCT07504458 · 150 participants (planned) · Start Jun 8, 2026 · Primary completion Mar 2027
Drug: QTX-2101 + ATRA; IV arsenic trioxide (ATO) + ATRA · For: Acute Promyelocytic Leukemia (APL); Acute Promyelocytic Leukaemia; Acute Promyelocytic Leukemia With PML-RARA and 2 more
Sites: Birmingham, Alabama; Duarte, California; Irvine, California · 39 sites in all
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07195695 · 400 participants (planned) · Start Jan 16, 2026 · Primary completion Feb 26, 2032
Drug: Zongertinib; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Fresno, California; Glendale, California; Orange, California · 205 sites in all
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06393374 · 1,530 participants (planned) · Start Jun 24, 2024 · Primary completion Dec 16, 2030
Drug: Pembrolizumab; Sacituzumab tirumotecan and 1 more · For: Triple-Negative Breast Cancer
Sites: Mobile, Alabama; Chandler, Arizona; Fountain Valley, California · 317 sites in all
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Pivotal-lookingRecruiting
Summit TherapeuticsIndustry
NCT06767514 · 780 participants (planned) · Start Feb 27, 2025 · Primary completion Apr 2028
Drug: Ivonescimab Injection; Pembrolizumab Injection · For: Non-Small Cell Lung Cancer
Sites: Chandler, Arizona; Phoenix, Arizona; Hot Springs, Arkansas · 292 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.